Abstract
Biphenylketones were identified as novel inhibitors of NFkappaB activation. Structure-activity studies led to the identification of compound 4c, which had good potency against osteoclasts (IC50=0.8 microM), showed oral activity, and was able to completely prevent inflammation and bone loss in vivo.
Copyright (c) 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / chemistry*
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use*
-
Arthritis / chemically induced
-
Arthritis / drug therapy*
-
Benzene Derivatives / chemistry*
-
Benzene Derivatives / pharmacology
-
Benzene Derivatives / therapeutic use*
-
Cell Line
-
Cell Survival / drug effects
-
Female
-
Inflammation / drug therapy
-
Ketones / chemistry*
-
Ketones / pharmacology
-
Ketones / therapeutic use*
-
Macrophages / cytology
-
Macrophages / drug effects
-
Macrophages / immunology
-
Mice
-
NF-kappa B / immunology
-
Osteoclasts / cytology
-
Osteoclasts / drug effects
-
Osteoporosis / drug therapy*
-
Polycyclic Aromatic Hydrocarbons / chemistry
-
Polycyclic Aromatic Hydrocarbons / pharmacology
-
Structure-Activity Relationship
-
Tumor Necrosis Factor-alpha / immunology
Substances
-
Anti-Inflammatory Agents
-
Benzene Derivatives
-
Ketones
-
NF-kappa B
-
Polycyclic Aromatic Hydrocarbons
-
Tumor Necrosis Factor-alpha